Pulmonary Arterial Hypertension Market

The global pulmonary arterial hypertension market is projected to reach USD 9 billion by 2027 from USD 7 billion in 2022, at a CAGR of 5% during the forecast period

To know about the assumptions considered for the study, Request for Free Sample Report

Pulmonary hypertension is high blood pressure in the pulmonary arteries, which carry oxygen-poor blood from heart to lungs. The major symptoms are shortness of breath, chest pain or pressure, dizziness or fainting, fatigue, and others. According to The American Journal of Managed Care, PAH is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Usually, PAH affects women aged between 30 and 60 years. The rising prevalence of the PAH across the globe is increasing the demand for treatment options, these factors are likely to have higher impact on the market growth in coming years.

In the report, the pulmonary arterial hypertension market is segmented into drug class, type, route of administration, distribution channel and region. Based on the drug class the market is segmented into endothelin receptor antagonists, SGC Stimulators, PDE-5 Inhibitors, prostacyclin and prostacyclin analogs and others. Increase in number of FDA approvals in the prostacyclin and prostacyclin analogs drug class is likely to have higher impact on the adoption and sales across the globe. For instance, In July 2021, Uptravi belonging to Prostacyclin and Prostacyclin Analogs segment received FDA approval for intravenous use in pulmonary arterial hypertension patients. Various SGC stimulators products under phase 2 and phase 3 clinical trials are likely to get approvals during the forecast period. For instance, Merck Sharp & Dohme LLC, candidate MK-5475 is under phase 2 clinical trial and expected to be launch in coming 3-4 years. The study is for MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).

Based on region the market is further divided into North America, Europe, Asia Pacific, and ROW (Rest of the World). Among the region North America is expected hold dominant share throughout the forecast period. The dominance is attributed to rising incidence & prevalence of pulmonary arterial hypertension in the region. Furthermore, rising investment in development & launch of new drugs in the market is likely to increase consumption hence contributing towards revenue growth in the region.

The major players operating in the pulmonary arterial hypertension market are United Therapeutics Corporation (US), BAYER (Germany), Gilead Sciences, Inc. (US), Johnson & Johnson (US), Viatris Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel) and among others.

To know about the assumptions considered for the study, download the pdf brochure

Want to explore hidden markets that can drive new revenue in Pulmonary Arterial Hypertension Market?

Unlock Insights

Scope of the Report

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. PAH occurs 3-5 times more often in females than in males. It tends to affect females between the ages of 30 and 60. Around 500-1000 new cases of PAH are diagnosed each year in the U.S. Rising prevalence is increasing demand for the treatment options hence projecting the market growth.

Global Pulmonary Arterial Hypertension Market

The research report categorizes the Pulmonary Arterial Hypertension Market into following segments.

Pulmonary Arterial Hypertension Market, By Drug Class

• Endothelin Receptor Antagonists
• SGC Stimulators
• PDE-5 Inhibitors
• Prostacyclin &Prostacyclin Analogs
• Others

Pulmonary Arterial Hypertension Market, By Route of Administration

• Oral
• Intravenous/ Subcutaneous
• Others

Pulmonary Arterial Hypertension Market, By Type

• Innovative
• Generics

Pulmonary Arterial Hypertension Market, By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

Pulmonary Arterial Hypertension Market, By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • ROE
• Asia Pacific
  • Japan
  • China
  • India
  • Rest Of APAC
• Rest Of the World (Row)
  • Latin America
  • Middle East & Africa

To speak to our analyst for a discussion on the above findings, click Speak to Analyst